Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study.
D012437:Adenosylmethionine Decarboxylase / Q000037:antagonists & inhibitors; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000578:Amidines / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007189:Indans / Q000494:pharmacology*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011073:Polyamines / Q000037:antagonists & inhibitors*; D011379:Prognosis; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome
D000578:Amidines; D000970:Antineoplastic Agents; D007189:Indans; D011073:Polyamines; C082408:4-amidinoindan-1-one 2'-amidinohydrazone; D012437:Adenosylmethionine Decarboxylase